AB SCIENCE Aktie

0,7610 EUR -0,0020 EUR -0,26 %

15:37:21

STU

0,7900 EUR -0,0100 EUR -1,25 %

25.11.2024

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.46,26 Mio. EUR

Div. Rendite0,00%

WKNA1CXBG

ISINFR0010557264

SymbolABSCF

AB SCIENCE Aktien News

Sortieren:Datum Meistgelesen

28.10.24GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

17.10.24GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

10.10.24GlobeNewswireAB Science: Revenues for the first half of 2024 and update on AB Science’s activities

WerbungAB SCIENCE-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.09.24GlobeNewswireAB Science announces a slight delay in the publication of its 2024 half-year financial report

26.09.24GlobeNewswireAB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

23.09.24GlobeNewswireAB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

08.07.24GlobeNewswireAB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

28.06.24GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

31.05.24GlobeNewswireAB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

29.05.24GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

15.05.24GlobeNewswireAB Science reports its revenues for the year 2023 and provides an update on its activities

13.05.24GlobeNewswireAB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

02.05.24GlobeNewswireAB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

30.04.24GlobeNewswireAB Science announces a slight delay in the publication of its 2023 annual financial report

03.04.24GlobeNewswireAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

13.03.24GlobeNewswireAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

07.03.24GlobeNewswireAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

06.03.24GlobeNewswireAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

01.03.24GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29.02.24GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

26.02.24GlobeNewswireAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26.01.24GlobeNewswireAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

15.01.24GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

28.11.23GlobeNewswireAB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

27.11.23GlobeNewswireAB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

29.09.23GlobeNewswireAB Science today reports its revenues for the first half of 2023 and provides an update on its activities

18.09.23GlobeNewswireAB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

26.06.23GlobeNewswireAB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

01.06.23GlobeNewswireAB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

17.05.23GlobeNewswireAB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

09.05.23GlobeNewswireAB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

28.04.23GlobeNewswireAB Science reports its revenues for the year 2022 and provides an update on its activities

27.04.23GlobeNewswireAB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

24.04.23GlobeNewswireAB Science announces the success of its capital increase by private placement for an amount of 15 million euros

21.04.23GlobeNewswireAB Science announces the implementation of a new strategy and the launch of a capital increase

18.04.23GlobeNewswireAB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

12.04.23GlobeNewswireAB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete

04.04.23GlobeNewswireAB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for respondin

15.03.23GlobeNewswireAB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

13.03.23GlobeNewswireAB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)

AB SCIENCE News

AB SCIENCE News: auf dieser Seite finden Sie alle AB SCIENCE News und Nachrichten zur AB SCIENCE Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AB SCIENCE News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AB SCIENCE News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.